Difference between revisions of "Acute myeloid leukemia trial demographics"
Jump to navigation
Jump to search
m |
m |
||
(One intermediate revision by the same user not shown) | |||
Line 7: | Line 7: | ||
!style="width: 17%"|Performance Status | !style="width: 17%"|Performance Status | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1182/blood.V79.2.313.313 Wiernik et al. 1992] |
|[[Acute_myeloid_leukemia#7.2B3d_.28standard-dose.29|7+3d (standard-dose)]] | |[[Acute_myeloid_leukemia#7.2B3d_.28standard-dose.29|7+3d (standard-dose)]] | ||
|55 (NR) | |55 (NR) | ||
Line 14: | Line 14: | ||
|ECOG 0-1: 86% | |ECOG 0-1: 86% | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1182/blood.V79.2.313.313 Wiernik et al. 1992] |
|[[Acute_myeloid_leukemia#7.2B3i|7+3i]] | |[[Acute_myeloid_leukemia#7.2B3i|7+3i]] | ||
|56 (NR) | |56 (NR) | ||
Line 49: | Line 49: | ||
|ECOG 0-1: 88% | |ECOG 0-1: 88% | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1182/blood-2011-06-361410 ADcomparison] |
|[[Acute_myeloid_leukemia#7.2B3d_.28standard-dose.29|7+3d (standard-dose)]] | |[[Acute_myeloid_leukemia#7.2B3d_.28standard-dose.29|7+3d (standard-dose)]] | ||
|43 (15-60)<sup>a</sup> | |43 (15-60)<sup>a</sup> | ||
Line 56: | Line 56: | ||
|KPS 90-100%: 80% | |KPS 90-100%: 80% | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1182/blood-2011-06-361410 ADcomparison] |
|[[Acute_myeloid_leukemia#7.2B3d_.28high-dose.29|7+3d (high-dose)]] | |[[Acute_myeloid_leukemia#7.2B3d_.28high-dose.29|7+3d (high-dose)]] | ||
|43 (15-60)<sup>a</sup> | |43 (15-60)<sup>a</sup> | ||
Line 65: | Line 65: | ||
|} | |} | ||
''<sup>a</sup>Age is not reported separately by arm. | ''<sup>a</sup>Age is not reported separately by arm. | ||
+ | |||
+ | '''This work is supported in part by [https://reporter.nih.gov/search/bweQKIeIwk-kOtL_oHSGSw/project-details/10705015 NCI U24 CA265879].''' | ||
+ | |||
[[Category:General reference pages]] | [[Category:General reference pages]] |
Latest revision as of 23:01, 27 June 2024
Study | Arm | Age, median (range) | Sex (%M/%F) | Race | Performance Status |
---|---|---|---|---|---|
Wiernik et al. 1992 | 7+3d (standard-dose) | 55 (NR) | 57/43 | NR | ECOG 0-1: 86% |
Wiernik et al. 1992 | 7+3i | 56 (NR) | 56/44 | NR | ECOG 0-1: 87% |
ECOG E1900 | 7+3d (standard-dose) | 47 (17-60) | 52/48 | NR | NR |
ECOG E1900 | 7+3d (high-dose) | 48 (18-60) | 50/50 | NR | NR |
HOVON 43 AML/SAKK 30/01 | 7+3d (standard-dose) | 67 (60-79) | 57/43 | NR | ECOG 0-1: 88% |
HOVON 43 AML/SAKK 30/01 | 7+3d (high-dose) | 67 (60-83) | 53/47 | NR | ECOG 0-1: 88% |
ADcomparison | 7+3d (standard-dose) | 43 (15-60)a | 48/52 | NR | KPS 90-100%: 80% |
ADcomparison | 7+3d (high-dose) | 43 (15-60)a | 60/40 | NR | KPS 90-100%: 82.5% |
aAge is not reported separately by arm.
This work is supported in part by NCI U24 CA265879.